On December 5th 2023 team SYDRA won business development grant (stage I) at venturekick.ch and got invitation for stage II competition among other winners.
AI-assisted geroprotectors (longevity drugs) discovery.
It has already been illustrated in animals that an organism’s health- & lifespan can be increased. The task of SYDRA is to develop systematically and on large-scale drugs able to increase health- and lifespan (called geroprotectors).
Being led by an enthusiastic and highly motivated founders’ team consisting of a biogerontologist Dr. Alex Dakhovnik and an AI specialist Dr. Pavlo Mozharovskyi, SYDRA deploys a feedback-based AI-driven drug-development platform for longevity. More precisely, AI-proposed drugs shall be screened in C. elegans nematodes with a short lifespan and elderly rodents along with toxicity testing and pathway identification. Within the foreseeable timeframe, potentially billions’ market can be addressed.
The VK Stage 1 funding shall be used for business development, more precisely for creating a business plan and communicating with potential investors.
via venturekick.ch